Akademik Veri Yönetim Sistemi
International Eurasian Conference on Biotechnology and Biochemistry (BioTechBioChem 2020), Ankara, Türkiye, 16 - 18 Aralık 2020, ss.227
Aim-Background: High Grade hepatocellular carcinoma (HCC) has a high risk of recurrence following resection
or liver transplantation. HCC is a tumor that has high resistance to conventional chemotherapeutics. Phenethyl
isothiocyanate (PEITC) is a novel antineoplastic agent that is being studied in many cancers. Therefore, there is
need for discovery of novel antitumor agents. The aim of the present study is to evaluate the antitumor efficacy of
PEITC on high grade HCC cell line SNU-449.
Materials and Methods: SNU-449 was obtained from the ATCC stock and cultured according to the company
protocol. Cell viability (MTT) assay was performed at 24, 48, 72th hour intervals to determine the minimum
effective concentration of PEITC in SNU-449. This concentration was used in cell proliferation (SRB), colony
formation and wound healing assays. The later two analysis was performed after 48 hours of incubation with the
effective dose of PEITC. All results are expressed as median (IQR= interquartile range).
Results: The MTT assay showed that antitumor efficacy of PEITC started from 10µM at 72 hours; absorbances in
10µM and control group were 0.431(IQR:0.458) and 0.67(IQR:0.049); respectively (p<0.05). Since this was the
minimum effective dose of PEITC, we used this concentration to perform other procedures. The results of SRB
assay in PEITC and control were 0.581(IQR:0.789) and 0.381(IQR:0.365), respectively (p>0.05). The colony
formation assay surviving fraction of PEITC treated cells was 19.35% relative to the untreated cells. The wound area
of PEITC treated cells and the control group were 1982061(IQR: 269014) µm2 and 528861(IQR:523150) µm2
;
respectively(p<0.05). Wound closure percent in PEITC and control groups were 10.35% (IQR:10.3) and
59.75%(IQR:15.4); respectively (p<0.05).
Conclusion: PEITC seems to decrease cell viability and cell invasion process in high grade hepatocellular
carcinoma cell line SNU-449. It is a good candidate for a novel antineoplastic agent. Intracellular effects of this
agent need further research